These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25415869)

  • 21. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.
    Deacon SW; Beeser A; Fukui JA; Rennefahrt UE; Myers C; Chernoff J; Peterson JR
    Chem Biol; 2008 Apr; 15(4):322-31. PubMed ID: 18420139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.
    McCarty SK; Saji M; Zhang X; Jarjoura D; Fusco A; Vasko VV; Ringel MD
    Endocr Relat Cancer; 2010 Dec; 17(4):989-99. PubMed ID: 20817787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.
    Ma Y; McCarty SK; Kapuriya NP; Brendel VJ; Wang C; Zhang X; Jarjoura D; Saji M; Chen CS; Ringel MD
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1314-22. PubMed ID: 23709653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PAK1 as a therapeutic target.
    Kichina JV; Goc A; Al-Husein B; Somanath PR; Kandel ES
    Expert Opin Ther Targets; 2010 Jul; 14(7):703-25. PubMed ID: 20507214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting PAK1.
    Semenova G; Chernoff J
    Biochem Soc Trans; 2017 Feb; 45(1):79-88. PubMed ID: 28202661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of allosteric inhibitors of p21-activated kinase.
    Viaud J; Peterson JR
    Methods Mol Biol; 2012; 928():67-79. PubMed ID: 22956134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
    Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
    J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors.
    Staben ST; Feng JA; Lyle K; Belvin M; Boggs J; Burch JD; Chua CC; Cui H; DiPasquale AG; Friedman LS; Heise C; Koeppen H; Kotey A; Mintzer R; Oh A; Roberts DA; Rouge L; Rudolph J; Tam C; Wang W; Xiao Y; Young A; Zhang Y; Hoeflich KP
    J Med Chem; 2014 Feb; 57(3):1033-45. PubMed ID: 24432870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rho family GTPase signaling through type II p21-activated kinases.
    Chetty AK; Ha BH; Boggon TJ
    Cell Mol Life Sci; 2022 Nov; 79(12):598. PubMed ID: 36401658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting group II PAKs in cancer and metastasis.
    Eswaran J; Soundararajan M; Knapp S
    Cancer Metastasis Rev; 2009 Jun; 28(1-2):209-17. PubMed ID: 19160016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?
    Azmi AS; Mohammad RM
    Future Med Chem; 2015; 7(1):5-7. PubMed ID: 25582328
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibitors of c-Jun N-terminal kinases: an update.
    Koch P; Gehringer M; Laufer SA
    J Med Chem; 2015 Jan; 58(1):72-95. PubMed ID: 25415535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Use of Nanomedicine to Target Signaling by the PAK Kinases for Disease Treatment.
    Wang Y; Minden A
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation.
    Su Y; Song P; Wang H; Hu B; Wang J; Cheng MS
    J Biomol Struct Dyn; 2020 Aug; 38(13):3825-3837. PubMed ID: 31490101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAK'n it in: identification of a selective PAK inhibitor.
    Bokoch GM
    Chem Biol; 2008 Apr; 15(4):305-6. PubMed ID: 18420134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
    Siekmann IK; Dierck K; Prall S; Klokow M; Strauss J; Buhs S; Wrzeszcz A; Bockmayr M; Beck F; Trochimiuk M; Gottschling K; Martens V; Khosh-Naucke M; Gerull H; Müller J; Behrmann L; Blohm M; Zahedi RP; Jeremias I; Sickmann A; Nollau P; Horstmann MA
    Blood Adv; 2018 Oct; 2(19):2554-2567. PubMed ID: 30301811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
    Tabusa H; Brooks T; Massey AJ
    Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.
    Ong CC; Gierke S; Pitt C; Sagolla M; Cheng CK; Zhou W; Jubb AM; Strickland L; Schmidt M; Duron SG; Campbell DA; Zheng W; Dehdashti S; Shen M; Yang N; Behnke ML; Huang W; McKew JC; Chernoff J; Forrest WF; Haverty PM; Chin SF; Rakha EA; Green AR; Ellis IO; Caldas C; O'Brien T; Friedman LS; Koeppen H; Rudolph J; Hoeflich KP
    Breast Cancer Res; 2015 Apr; 17(1):59. PubMed ID: 25902869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p21-Activated kinases as promising therapeutic targets in hematological malignancies.
    Wu A; Jiang X
    Leukemia; 2022 Feb; 36(2):315-326. PubMed ID: 34697424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The subcellular localization of type I p21-activated kinases is controlled by the disordered variable region and polybasic sequences.
    Sun X; Su VL; Calderwood DA
    J Biol Chem; 2019 Sep; 294(39):14319-14332. PubMed ID: 31391252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.